Radiopharmaceutical manufacturer IsoRay’s Proxcelan with Cesium -131, an isotope developed by the Richland, Wash.-based firm’s IsoRay Medical subsidiary, is the subject of four scientific abstracts scheduled for presentation at the 2007 American Association of Physicists in Medicine (AAPM) conference in Minneapolis next week, the company said.

The studies illustrate the radiobiological characteristics and related dosimetric outcomes in treatment planning using the firm’s Proxcelan with Cesium-131 in brachytherapy for the treatment of prostate cancer, IsoRay said.